SCHEMBL30370293

SCHEMBL30370293

O=C(NC1CCN(C(=O)O)C1)c1ncc(-c2cccc(C(F)(F)F)c2)o1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 1/20 0.54
▸ HDAC6 Q9UBN7 1/20 0.54
▸ RIPK1 Q13546 1/20 0.42
▸ USP30 Q70CQ3 2/20 0.42
▸ GRIN1 Q05586 2/20 0.41
▸ GRIN2B Q13224 2/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ KCNH2 Q12809 1/20 0.41
▸ TEAD1 P28347 2/20 0.41
▸ F2R P25116 1/20 0.41
▸ EPHX2 P34913 1/20 0.41
▸ KIF11 P52732 1/20 0.41
▸ MAP3K7 O43318 1/20 0.40
▸ TAB1 Q15750 1/20 0.40
▸ RPS6KB1 P23443 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27418109 0.88 USP30 (0.56) HDAC1HDAC6RIPK1USP30
SCHEMBL30230685 0.86 MAP3K7 (0.42) HDAC1HDAC6USP30KCNH2MAP3K7
SCHEMBL25676690 0.85 USP30 (0.54) HDAC1HDAC6USP30
SCHEMBL31017667 0.85 USP30 (0.54) HDAC1HDAC6USP30
SCHEMBL30370273 0.84 ADCY1 (0.44) USP30KCNH2TEAD1EPHX2
SCHEMBL25305510 0.78 HDAC1 (0.50) HDAC1HDAC6RIPK1GRIN1GRIN2B
SCHEMBL25258959 0.78 HDAC1 (0.50) HDAC1HDAC6GRIN1GRIN2BCYP2C9
SCHEMBL25258088 0.78 HDAC1 (0.50) HDAC1HDAC6RIPK1GRIN1GRIN2B
SCHEMBL28971352 0.78 HDAC1 (0.50) HDAC1HDAC6RIPK1GRIN1GRIN2B
SCHEMBL24073259 0.78 HDAC1 (0.51) HDAC1HDAC6USP30GRIN1GRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4157834-A1 N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION Mission Therapeutics Limited (GB) 2023-04-05 — — EP disclosed
Send feedback